The penicillins

Mayo Clinic Proceedings

Volumn 74, Issue 3, 1999, Pages 290-307

  Wright, Alan J ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN DERIVATIVE; PENICILLIN G;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN;

EID: 0033050175     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.3.290     Document Type: Conference Paper

References (58)

1. Tomasz A. From penicillin-binding proteins to the lysis and death of bacteria: a 1979 view. Rev Infect Dis 1979;l:434-467
2. Green RL, Lewis JE, Kraus SJ, Frederickson EL. Elevated plasma procaine concentrations after administration of procaine penicillin G. N Engl J Med 1974;291:223-226
3. Hackbarth CJ, Chambers HF. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob Agents Chemother 1989;33:991-994
4. Gilbert DN, Sanford JP. Methicillin: critical appraisal after a decade of experience. Med Clin North Am 1970 Sep;54:1113-1125
5. Amoxicillin. Med Lett Drugs Ther 1974;16:49-50
6. Dajani AS, Taubert KA, Wilson W, Böiger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997;277:1794-1801
7. Schelfe RT, Neu HC. Bacampicillin hydrochloride: chemistry, pharmacology, and clinical use. Pharmacotherapy 1982;2:313321
8. Nunnery AW, Hamilton WD, Riley HD Jr. Carbenicillin: in-vivo synergism and combined therapy. J Infect Dis 1970;122(Suppl):S78S83
9. Smith CB, Wilfert JN, Dans PE, Kurrus TA, Finland M. In vitro activity of carbenicillin and results of treatment of infections due to Pseudomonas with carbenicillin singly and in combination with gentamicin. J Infect Dis 1970;122(Suppl):S14-S25
10. Selwyn S. The evolution of the broad-spectrum penicillins. J Antimicrob Chemother 1982;9(Suppl B):l-10
11. Meyers BR, Hirschman SZ, Strougo L, Srulevitch E. Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics. Antimicrob Agents Chemother 1980:17:608-611
12. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978; 14:829837
13. Bergan T. Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob Agents Chemother 1978;14:801-806
14. Mangione A, Boudinot FD, Schultz RM, Jusko WJ. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob Agents Chemother 1982;21:428-435
15. Fu KP, Neu HC. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother 1978;13:930-938
16. Bodey GP, Le Blanc B. Piperacillin: in vitro evaluation. Antimicrob Agents Chemother 1978;14:78-87
17. Wise R, Gillett AP, Andrews JM, Bedford KA. Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother 1978;13:559-565
18. White GW, Malow JB, Zimelis VM, Pahlavanzadeh H, Panwalker AP, Jackson GG. Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother 1979;15:540543
19. Coppens L, Klastersky J. Comparative study of anti-Pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother 1979;15:396-399
20. White AR, Comber KR, Sutherland R. Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1980;18:182-189
21. Basker MJ, Edmondson RA, Sutherland R. Comparative antibacterial activity of azlocillin, mezlocillin, carbenicillin and ticarcillin and relative stability to beta-lactamases of Pseudomonas aeruginosa and Klebsiella aerogenes. Infection 1979;7:67-73
22. Pancoast SJ, Jahre JA, Neu HC. Mezlocillin in the therapy of serious infections. Am J Med 1979;67:747-752
23. Pancoast S, Prince AS, Francke EL, Neu HC. Clinical evaluation of piperacillin therapy for infection. Arch Intern Med 1981:141:14471450
24. Winston DJ, Murphy W, Young LS, Hewitt WL. Piperacillin therapy for serious bacterial infections. Am J Med 1980:69:255-261
25. Ellis CJ, Geddes AM, Davey PG, Wise R, Andrews JM, Grimley RP. Mezlocillin and azlocillin: an evaluation of two new -lactam antibiotics. J Antimicrob Chemother 1979;5:517-525
26. Issell BF, Bodey GP. Mezlocillin for treatment of infections in cancer patients. Antimicrob Agents Chemother 1980;17:10081013
27. Wade JC, Schimpft SC, Newman KA, Fortner CL, Moody MR, Young VM, et al. Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother 1980:18:299-306
28. Wittmann DH. A clinical evaluation of piperacillin in intraabdominal infections [abstract]. Clin Ther 1980;6(Suppl A):35
29. Wade JC, Schimpft SC, Newman KA, Fortner CL, Standiford HC, Wiernik PH. Piperacillin or ticarcillin plus amikacin: a doubleblind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1981:71:983-990
30. Gould IM, Wise R. Lactamase inhibitors. In: Peterson PK, Verhoef J, editors. The Antimicrobial Agents Annual 3. Amsterdam: Elsevier Science Publishers; 1988. pp 63-76
31. Bush K. Characterization of beta-lactamases. Antimicrob Agents Chemother 1989:33:259-263
32. Richmond MH, Sykes RB. The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973:9:31-88
33. Moosdeen F, Keeble J, Williams JD. Induction/inhibition of chromosomal -lactamases by -lactamase inhibitors. Rev Infect Dis 1986; 8(Suppl 5):S562-S568
34. Amoxicillin-clavulanic acid (Augmentin). Med Lett Drugs Ther 1984; 26:99-100
35. Slocombe B, Beale A, Boon R, et al. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid. Postgrad Med Sep/Oct 1984; p 29
36. Goldstein E, Reinhard! J, Murray P, Finegold S. Animal and human bite wounds: a comparative study of Augmentin versus penicillin +/dicloxacillin. Postgrad Med Sept/Oct 1984; p 105
37. Barry AL, Ayers LW, Gavan TL, Gerlach EH, Jones RN. In vitro activity of ticarcillin plus clavulanic acid against bacteria isolated in three centers. Eur J Clin Microbiol 1984;3:203-206
38. Fuchs PC, Barry AL, Thornsberry C, Jones RN. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob Agents Chemother 1984;25:392-394
39. Clarke AM, Zemcov SJV. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other -lactams. J Antimicrob Chemother 1984:13:121-128
40. Roselle GA, Bode R, Hamilton B, Bibler M, Sullivan R, Douce R, et al. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. Antimicrob Agents Chemother 1985:27:291-296
41. Meunier F, Snoeck R, Lagast H, Woussen F, Klastersky J. Empirical antimicrobial therapy with Timentin plus amikacin in febrile granulocytopenic cancer patients. J Antimicrob Chemother 1986; 17(Suppl C):195-201
42. Retsema JA, English AR, Girard A, Lynch JE, Anderson M, Brennan L, et al. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis 1986;8(Suppl 5):S528S534
43. Wexler HM, Harris B, Carter WT, Finegold SM. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother 1985;27:876-878
44. Loftier L, Bauernfeind A, Key! W, Hoffstedt B, Piergies A, Lenz W. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Rev Infect Dis l986;8(Suppl 5):S593-S598
45. Giamarellou H, Trouvas G, Avlami A, Aravantinos D, Daikos GK. Efficacy of sulbactam plus ampicillin in gynecologic infections. Rev Infect Dis 1986;8(Suppl 5):S579-S582
46. Study Group of Intraabdominal Infections. A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections: a preliminary report. Rev Infect Dis 1986;8(Suppl 5):S583-S588
47. Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E, et al. Piperacillin/tazobactam versus imipenem/ cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993:176:255-261
48. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group. Results of the North American trial of piperacillin/ tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Eur J Surg Suppl 1994;573:61-66
49. Eklund AE, Nord CE (Swedish Study Group). A randomized multicenter trial of piperacillin/tazobactam versus imipenem/ cilastatin in the treatment of severe intra-abdominal infections. J Antimicrob Chemother 1993;31(Suppl A):79-85
50. Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, et al. Piperacillin-tazobactam versus imipenemcilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992:36:2766-2773
51. Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW (Piperacillin/Tazobactam Skin and Skin Structure Study Group). Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob Agents Chemother 1993;37:1580-1586
52. Sweet RL, Roy S, Faro S, O'Brien WF, Sanfilippo JS, Seidlin M (Piperacillin/Tazobactam Study Group). Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1994;83:280-286
53. Joshi M, Solmkin JS, Bernstein JM (Piperacillin/Tazobactam Pneumonia Study Group). Open, randomized multicenter comparison of piperacillin/tazobactam vs. ceftazidime, both plus tobramycin, in hospital-acquired lower respiratory tract infection [abstract]. Presented at the 6th International Congress for Infectious Diseases. Boston; 1994
54. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al (International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer). Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-452
55. Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 1968;38:159188
56. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985;312:1229-1232
57. Borish L, Tamir R, Rosenwasser U. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol 1987;80:314-319
58. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med 1977;296:663-670